Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ofer Zimmerman

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology|June 28, 2016
Distinct mutations at the same positions of STAT3 cause either loss or gain of functionPrabha Chandrasekaran, Ofer Zimmerman, Michelle Paulson, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Determinants of human versus mosquito cell entry by the Chikungunya virus envelope proteinsXiaohui Ju, William W Hannon, Tomasz Kaszuba, et al.
Cell Reports|October 6, 2024
The VLDLR entry receptor is required for the pathogenesis of multiple encephalitic alphavirusesSathvik Palakurty, Saravanan Raju, Alan Sariol, et al.
Frontiers in Immunology|July 30, 2019
<i>STAT1</i> Gain-of-Function Mutations Cause High Total STAT1 Levels With Normal DephosphorylationOfer Zimmerman, Peter Olbrich, Alexandra F Freeman, et al.
Open Forum Infectious Diseases|December 12, 2017
Risks of Ruxolitinib in <i>STAT1</i> Gain-of-Function-Associated Severe Fungal DiseaseOfer Zimmerman, Berenice Rösler, Christa S Zerbe, et al.
Cell Host & Microbe|February 21, 2020
An Evolutionary Insertion in the Mxra8 Receptor-Binding Site Confers Resistance to Alphavirus Infection and PathogenesisArthur S Kim, Ofer Zimmerman, Julie M Fox, et al.
The Journal of Allergy and Clinical Immunology|November 8, 2017
Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutationsAlexander Vargas-Hernández, Emily M Mace, Ofer Zimmerman, et al.
Journal of Clinical Immunology|May 4, 2022
Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutationsPilar Blanco Lobo, Paloma Guisado-Hernández, Isabel Villaoslada, et al.
Cell|October 7, 2023
Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8Ofer Zimmerman, Maxwell I Zimmerman, Saravanan Raju, et al.
JCI Insight|January 4, 2024
Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activityOfer Zimmerman, Alexa Michelle Altman Doss, Baoling Ying, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology|June 28, 2016
Distinct mutations at the same positions of STAT3 cause either loss or gain of functionPrabha Chandrasekaran, Ofer Zimmerman, Michelle Paulson, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Determinants of human versus mosquito cell entry by the Chikungunya virus envelope proteinsXiaohui Ju, William W Hannon, Tomasz Kaszuba, et al.
Cell Reports|October 6, 2024
The VLDLR entry receptor is required for the pathogenesis of multiple encephalitic alphavirusesSathvik Palakurty, Saravanan Raju, Alan Sariol, et al.
Frontiers in Immunology|July 30, 2019
<i>STAT1</i> Gain-of-Function Mutations Cause High Total STAT1 Levels With Normal DephosphorylationOfer Zimmerman, Peter Olbrich, Alexandra F Freeman, et al.
Open Forum Infectious Diseases|December 12, 2017
Risks of Ruxolitinib in <i>STAT1</i> Gain-of-Function-Associated Severe Fungal DiseaseOfer Zimmerman, Berenice Rösler, Christa S Zerbe, et al.
Cell Host & Microbe|February 21, 2020
An Evolutionary Insertion in the Mxra8 Receptor-Binding Site Confers Resistance to Alphavirus Infection and PathogenesisArthur S Kim, Ofer Zimmerman, Julie M Fox, et al.
The Journal of Allergy and Clinical Immunology|November 8, 2017
Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutationsAlexander Vargas-Hernández, Emily M Mace, Ofer Zimmerman, et al.
Journal of Clinical Immunology|May 4, 2022
Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutationsPilar Blanco Lobo, Paloma Guisado-Hernández, Isabel Villaoslada, et al.
Cell|October 7, 2023
Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8Ofer Zimmerman, Maxwell I Zimmerman, Saravanan Raju, et al.
JCI Insight|January 4, 2024
Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activityOfer Zimmerman, Alexa Michelle Altman Doss, Baoling Ying, et al.
Pageof 3